生物制药企业Scienture Holdings, Inc.（SCNX）宣布，其核心产品Arbli™（氯沙坦钾）口服混悬液再度获得一项关键专利授权。这标志着该药物在知识产权保护方面取得里程碑式进展，已累计拥有三项核心专利护城河。
最新专利授权将有效构筑技术壁垒，确保Arbli™在高血压治疗领域的市场独占地位延续至2041年。通过强化知识产权布局，Scienture不仅巩固了产品商业价值，更为长期营收增长注入确定性。此次专利拓展进一步凸显公司对创新研发的持续投入与战略前瞻性。
生物制药企业Scienture Holdings, Inc.（SCNX）宣布，其核心产品Arbli™（氯沙坦钾）口服混悬液再度获得一项关键专利授权。这标志着该药物在知识产权保护方面取得里程碑式进展，已累计拥有三项核心专利护城河。
最新专利授权将有效构筑技术壁垒，确保Arbli™在高血压治疗领域的市场独占地位延续至2041年。通过强化知识产权布局，Scienture不仅巩固了产品商业价值，更为长期营收增长注入确定性。此次专利拓展进一步凸显公司对创新研发的持续投入与战略前瞻性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.